David Amsellem
Stock Analyst at Piper Sandler
(4.57)
# 221
Out of 4,859 analysts
145
Total ratings
59.48%
Success rate
18.14%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Reiterates: Neutral | $115 | $132.82 | -13.42% | 1 | Jun 12, 2025 | |
| AMGN Amgen | Maintains: Overweight | $329 → $328 | $295.52 | +10.99% | 3 | May 16, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $24 → $18 | $10.23 | +75.95% | 6 | May 15, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Neutral | $36 → $37 | $29.58 | +25.08% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $176 → $147 | $110.17 | +33.43% | 14 | May 7, 2025 | |
| NBIX Neurocrine Biosciences | Reiterates: Overweight | $160 → $154 | $125.12 | +23.08% | 10 | May 6, 2025 | |
| BMY Bristol-Myers Squibb Company | Initiates: Overweight | $65 | $50.67 | +28.29% | 1 | Apr 22, 2025 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $128 → $131 | $71.17 | +84.07% | 7 | Apr 3, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $36 → $32 | $26.41 | +21.17% | 8 | Mar 21, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Neutral | $3 → $4 | $4.43 | -9.60% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $13 | $13.83 | -6.00% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $9.07 | +10.25% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $17.57 | +70.75% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $9.49 | +36.99% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $9 | $6.61 | +36.16% | 1 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $11 | $7.89 | +39.42% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $37 | $30.84 | +19.97% | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $61.99 | +9.70% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $41 → $36 | $32.60 | +10.43% | 15 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $5.52 | -45.65% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $24.03 | +74.78% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $3.25 | +208.17% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $0.71 | +2,878.72% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $106.50 | +6.10% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $33.06 | +27.04% | 3 | Oct 16, 2023 |
Biogen
Jun 12, 2025
Reiterates: Neutral
Price Target: $115
Current: $132.82
Upside: -13.42%
Amgen
May 16, 2025
Maintains: Overweight
Price Target: $329 → $328
Current: $295.52
Upside: +10.99%
Organon & Co.
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $10.23
Upside: +75.95%
Collegium Pharmaceutical
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $29.58
Upside: +25.08%
Jazz Pharmaceuticals
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $110.17
Upside: +33.43%
Neurocrine Biosciences
May 6, 2025
Reiterates: Overweight
Price Target: $160 → $154
Current: $125.12
Upside: +23.08%
Bristol-Myers Squibb Company
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $50.67
Upside: +28.29%
Corcept Therapeutics
Apr 3, 2025
Maintains: Overweight
Price Target: $128 → $131
Current: $71.17
Upside: +84.07%
Amphastar Pharmaceuticals
Mar 21, 2025
Maintains: Neutral
Price Target: $36 → $32
Current: $26.41
Upside: +21.17%
Xeris Biopharma Holdings
Mar 7, 2025
Reiterates: Neutral
Price Target: $3 → $4
Current: $4.43
Upside: -9.60%
Mar 6, 2025
Maintains: Overweight
Price Target: $16 → $13
Current: $13.83
Upside: -6.00%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $9.07
Upside: +10.25%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $17.57
Upside: +70.75%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $9.49
Upside: +36.99%
Jan 2, 2025
Maintains: Overweight
Price Target: $26 → $9
Current: $6.61
Upside: +36.16%
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $7.89
Upside: +39.42%
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $30.84
Upside: +19.97%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $61.99
Upside: +9.70%
Sep 11, 2024
Downgrades: Neutral
Price Target: $41 → $36
Current: $32.60
Upside: +10.43%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $5.52
Upside: -45.65%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $24.03
Upside: +74.78%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $3.25
Upside: +208.17%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $0.71
Upside: +2,878.72%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $106.50
Upside: +6.10%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $33.06
Upside: +27.04%